Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Must speak and understand oral and written English.
Must have probable bvFTD.
Must have a global Clinical Dementia Rating (CDR) score of 0.5-1 and a Mini Mental State Examination (MMSE) score ≥20 to reflect early stages of disease.
Must have 1 informant/caregiver who, in the Investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide accurate information about the participant's behaviors as well as cognitive and functional abilities.
Must be ambulatory or able to walk with assistance and not be institutionalized.
Must speak and understand oral and written English.
Must be in good general health determined by Investigator.
You may not be if
Concomitant motor neuron disease with limb or bulbar weakness which, in the opinion of the Investigator, may affect performance over the course of the study. Participants with bvFTD with motor neuron disease are otherwise allowed to participate.
Known presence of a structural brain lesion that could reasonably explain symptoms.
Diagnosis of Alzheimer's disease and/or known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or neuropathological evidence for Alzheimer's disease as a cause of syndrome.
History of other acute or chronic neurological or psychiatric conditions that are unrelated and may confound a diagnosis of bvFTD and that, in the opinion of the Investigator, may affect cognition, behavior, or ability to complete the study.
History of severe alcohol or substance abuse.
History of disorders that could confound a diagnosis of bvFTD.
Use of allowed chronic medications at doses that have not been stable for at least 4 weeks prior to Screening.
Current use of psychoactive medication that will interfere with accurate assessment of cognition (as assessed by the Investigator)
History of alcohol or substance abuse.
Current use of psychoactive medication that will interfere with accurate assessment of cognition (as assessed by the Investigator).
Clareo Health | Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
